Navigation Links
OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
Date:9/22/2010

BOTHELL, WA and VANCOUVER, Sept. 22 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today publication of results from a randomized Phase 2 trial in the Journal of Clinical Oncology. The trial results showed a survival benefit with the investigational agent OGX-011/TV1011 (custirsen) in patients with advanced prostate cancer. The median overall survival for patients who were treated with custirsen plus first-line docetaxel/prednisone was 23.8 months compared to 16.9 months for patients treated with docetaxel/prednisone alone. The manuscript was published in the September 20, 2010 issue of the journal.

"The survival analysis provides a strong suggestion of clinical benefit with a hazard ratio consistent with a 50% reduction in the rate of death favoring custirsen treatment," said Dr. Kim Chi, Principal Investigator and medical oncologist at BC Cancer Agency. "These data provide the foundation and rationale for the upcoming SYNERGY Phase 3 trial evaluating custirsen in approximately 800 men with metastatic CRPC."

The study investigators concluded custirsen in combination with docetaxel was well tolerated. Furthermore, they noted that adverse events associated with custirsen, including lymphopenia, rigors and fever have been reported with other antisense therapeutics.

Analysis of trial results also showed:

- The observed survival benefit was attributed to the custirsen treatment rather than duration of docetaxel treatment or administration of subsequent therapies; - Fewer patients discontinued study therapy because of disease progression when custirsen was given (18% in custirsen plus docetaxel arm versus 39% in docetaxel arm), resulting in a greater number of treatment cycles administered (median of 9 cycles in custirsen plus docetaxel arm versus 7 cycles in docetaxel arm); - Statistically significant declines in serum clus
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Reports Second Quarter Financial Results
2. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
3. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
6. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
7. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
8. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
9. OncoGenex Reports Third Quarter 2009 Financial Results
10. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
11. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... NEW YORK , Aug. 21, 2014 /PRNewswire/ ... OTCM) congratulates Immune Pharmaceuticals Inc., a biotechnology company, ... Capital Market.  Immune previously traded on OTCQX®, the ... operated by OTC Markets Group. Logo - ... Immune Pharmaceuticals on the successful execution of its ...
(Date:8/21/2014)... Aug. 21, 2014  Four-dimensional (4-D) printing develops ... on external stimuli such as changes in temperature. ... disruptive effect in multiple industries.  In the near ... by printing objects ranging from human organs to ... Logo - http://photos.prnewswire.com/prnh/20140820/138289 ...
(Date:8/21/2014)... Sofia, Bulgaria (PRWEB) August 21, 2014 ... was released today by Ontotext . Now ... and semantic analysis of structured and unstructured data is ... of the cost of enterprise technology. Organizations that do ... approaches for data management can use S4 since there ...
(Date:8/21/2014)... MA (PRWEB) August 21, 2014 ... company, has been recognized as one of the ... | 5000 magazine for the 2nd consecutive year. ... its 33rd annual Inc. 500|5000, an exclusive ranking ... represents the most comprehensive look at the most ...
Breaking Biology Technology:OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3
... ... awards program. In keeping with extensions given in previous years, the 2010 extended deadline is ... Needham, MA ... Best Practices awards program. In keeping with extensions given in previous years, the 2010 extended ...
... , WASHINGTON , Jan. 22 The ... hold a conference call hosted by Robert W. Musslewhite , Chief ... discuss the Company,s financial results for the quarter ended December 31, ... 2010 , at 6:00 p.m., Eastern Time .  The Company plans ...
... , EATONTOWN, N.J. , Jan. 22 ... field of biologic products for regenerative healing, announced today that its ... is designed to discourage coercive or unfair takeover tactics and to ... in the event that an unsolicited offer is made to acquire ...
Cached Biology Technology:The 2010 Bio-IT World Best Practices Deadline Has Been Extended 2The 2010 Bio-IT World Best Practices Deadline Has Been Extended 3The Advisory Board Company Schedules Third Quarter Conference Call for February 4, 2010 2Osteotech, Inc. Adopts Stockholder Rights Plan 2Osteotech, Inc. Adopts Stockholder Rights Plan 3
(Date:8/22/2014)... Anyone who has suffered an injury can probably remember ... signs that the body is fighting back against the ... programs are activated to aid in tissue regeneration. An ... repair and regeneration, helping the body to heal after ... mechanism may interfere with healing in situations in which ...
(Date:8/22/2014)... strong antioxidants and can reduce free radical ... against oxidative stress? Jianbo Zhao and co-workers ... Medical University, China discovered that green tea ... neuronal apoptosis, indicating green tea polyphenols play ... under oxidative stress. The relevant study has ...
(Date:8/21/2014)... team of scientists including researchers from the University of Georgia ... as canolain the journal Science . Their discovery paves ... used widely in farming and industry. , Canola is ... the winter crop is increasingly cultivated in Georgia. Canola oil ... of saturated fat and rich supply of omega-3 fatty acids, ...
Breaking Biology News(10 mins):Tissue regeneration using anti-inflammatory nanomolecules 2Canola genome sequence reveals evolutionary 'love triangle' 2
... Boston, Mass.Researchers at Boston Children,s Hospital have found that ... could potentially protect the fragile lungs of premature babies ... by inflammation. The findings explain earlier research ... called mesenchymal stem cells (MSCs) could help reduce lung ...
... fast. That,s an essential characteristic of what makes them cancer ... continuously growing and dividing, far outstripping our normal cells. To ... CSHL Professor Adrian Krainer and his team have found ... in the process specifically kill cancer cells. Nearly 90 ...
... as regenerating damaged tissues or organs have generated a ... types of applications are exciting, it is a long journey ... cells on human health will most likely come from their ... to generate stem cells by reprogramming cells from patients, skin ...
Cached Biology News:Microscopic packets of stem cell factors could be key to preventing lung disease in babies 2Microscopic packets of stem cell factors could be key to preventing lung disease in babies 3Team uses antisense technology that exploits gene splicing mechanism to kill cancer cells 2Team uses antisense technology that exploits gene splicing mechanism to kill cancer cells 3The role of stem cells in developing new drugs 2
... INTERFERin is a new-generation siRNA transfection ... efficiency at 1 nM siRNA in a ... with excellent cell viability. Using low siRNA ... effects observed when transfecting siRNA at higher ...
... and Tissue Staining Kits are intended for ... of histological and cytological specimens. These kits ... manufactured by either R&D Systems or by ... the formation of the Avidin-Biotin Complex (ABC) ...
... Cellular uptake of long double stranded RNA ... interference in a diverse group of organisms ... RNA interference leads to the inhibition of ... of the target messenger RNA (mRNA). Attempts ...
... is an easy-to-use siRNA transfection reagent that ... genes in a variety of cell lines. ... an optimized, straightforward protocol. High levels of ... following transfection of 20 to 100 nM ...
Biology Products: